Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciprofloxacin Prophylaxis for Meningococcal Meningitis Epidemic
NCT03431675Phase 4Withdrawn
- Sponsor
- Illumina
- Start
- Mar 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ciprofloxacin in meningococcal meningitis (3 arms), sponsored by Illumina. Primary endpoint: Meningitis attack rate at 2 months. Planned start Mar 2019; status: withdrawn.
02
Drugs
ciprofloxacin
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT03431675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03431675.